<DOC>
	<DOCNO>NCT01527032</DOCNO>
	<brief_summary>High-dose melphalan ( MEL ) autologous stem cell transplant ( SCT ) effective therapy systemic AL amyloidosis ( AL ) , treatment-related mortality ( TRM ) historically high . The investigator perform phase II trial risk-adapted SCT follow adjuvant dexamethasone ( dex ) thalidomide ( thal ) attempt reduce TRM improve response rate . Patients newly diagnose AL involve £2 organ system assign MEL 100 , 140 , 200 mg/m2 SCT , base age , renal function cardiac involvement . Patients persistent clonal plasma cell disease 3 month post-SCT receive 9 month adjuvant thal/dex ( dex history deep vein thrombosis neuropathy ) . TRM 4.4 % . Thirty-one patient begin adjuvant therapy , 16 ( 52 % ) complete 9 month treatment 13 ( 42 % ) achieve improvement hematological response . By intention-to-treat , overall hematological response rate 71 % ( 36 % complete response ) 44 % organ response . With median follow-up 31 month , 2-year survival 84 % ( 95 % confidence interval : 73 % , 94 % ) . Risk-adapted SCT adjuvant thal/ dex feasible result low TRM high hematological organ response rate AL patient .</brief_summary>
	<brief_title>Risk-adapted Therapy Primary Systemic ( AL ) Amyloidosis</brief_title>
	<detailed_description>High-dose melphalan ( MEL ) autologous stem cell transplant ( SCT ) effective therapy systemic AL amyloidosis ( AL ) , treatment-related mortality ( TRM ) historically high . The investigator perform phase II trial risk-adapted SCT follow adjuvant dexamethasone ( dex ) thalidomide ( thal ) attempt reduce TRM improve response rate . Patients ( n=45 ) newly diagnose AL involve £2 organ system assign MEL 100 , 140 , 200 mg/m2 SCT , base age , renal function cardiac involvement . Patients persistent clonal plasma cell disease 3 month post-SCT receive 9 month adjuvant thal/dex ( dex history deep vein thrombosis neuropathy ) . Organ involvement kidney ( 67 % ) , heart ( 24 % ) , liver/GI ( 22 % ) peripheral nervous system ( 18 % ) , 31 % two organ involve . TRM 4.4 % . Thirty-one patient begin adjuvant therapy , 16 ( 52 % ) complete 9 month treatment 13 ( 42 % ) achieve improvement hematological response . By intention-to-treat , overall hematological response rate 71 % ( 36 % complete response ) 44 % organ response . With median follow-up 31 month , 2-year survival 84 % ( 95 % confidence interval : 73 % , 94 % ) . Risk-adapted SCT adjuvant thal/ dex feasible result low TRM high hematological organ response rate AL patient . ( British Journal Haematology 2007 ; 139:224-33 )</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>None</criteria>
	<gender />
	<minimum_age />
	<maximum_age />
	<verification_date>July 2011</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>stem cell transplant</keyword>
</DOC>